| First Author | Bacioglu M | Year | 2016 |
| Journal | Neuron | Volume | 91 |
| Issue | 1 | Pages | 56-66 |
| PubMed ID | 27292537 | Mgi Jnum | J:239634 |
| Mgi Id | MGI:5829331 | Doi | 10.1016/j.neuron.2016.05.018 |
| Citation | Bacioglu M, et al. (2016) Neurofilament Light Chain in Blood and CSF as Marker of Disease Progression in Mouse Models and in Neurodegenerative Diseases. Neuron 91(1):56-66 |
| abstractText | A majority of current disease-modifying therapeutic approaches for age-related neurodegenerative diseases target their characteristic proteopathic lesions (alpha-synuclein, Tau, Abeta). To monitor such treatments, fluid biomarkers reflecting the underlying disease process are crucial. We found robust increases of neurofilament light chain (NfL) in CSF and blood in murine models of alpha-synucleinopathies, tauopathy, and beta-amyloidosis. Blood and CSF NfL levels were strongly correlated, and NfL increases coincided with the onset and progression of the corresponding proteopathic lesions in brain. Experimental induction of alpha-synuclein lesions increased CSF and blood NfL levels, while blocking Abeta lesions attenuated the NfL increase. Consistently, we also found NfL increases in CSF and blood of human alpha-synucleinopathies, tauopathies, and Alzheimer's disease. Our results suggest that CSF and particularly blood NfL can serve as a reliable and easily accessible biomarker to monitor disease progression and treatment response in mouse models and potentially in human proteopathic neurodegenerative diseases. |
